Herpes zoster infection after liver transplantation in patients receiving induction therapy with alemtuzumab.
BACKGROUND
The incidence of herpes zoster (HZ) infection in liver transplant recipients prior to the use of induction therapy with monoclonal antibodies has been reported as being 1.2-18%. We studied the occurrence of HZ in liver transplant recipients that received induction therapy with alemtuzumab (Campath 1H).


METHODS
This was a retrospective review of primary liver transplant recipients who received alemtuzumab as induction therapy at our center. HZ infection was diagnosed clinically as the presence of a characteristic vesicular rash in a dermatomal distribution without any further virological confirmation.


RESULTS
A total of 118 liver transplant recipients were treated with alemtuzumab between August 2002 and August 2005. Twelve patients developed HZ infection, and the cumulative probability of a patient developing HZ infection by 36 months post-transplant +/-1 SE was estimated as 16.5 +/- 5.0%. The median time for onset of the infection was 10.2 months (range 4.7-30.7) after the transplant. All patients had only one dermatomal distribution, and none developed systemic infection or complications such as postherpetic neuropathy. All patients except one were treated with systemic intravenous acyclovir. One patient received famciclovir. All of the patients had received ganciclovir during the post-transplant period but were not receiving any other antiviral medication at the time of the infection.


CONCLUSIONS
Herpes zoster infection has previously been reported as a frequent complication of liver transplantation. Our study suggests that it occurs in approximately 16% of patients receiving induction therapy with alemtuzumab. Although alemtuzumab is a powerful immunosuppressive agent and there is still little information regarding its long-term safety when used in liver transplantation, our data do not suggest any increase in the occurrence and complications of HZ.
Alcaide
Maria L
ML
Department of Infectious Diseases, Miller School of Medicine, Miami, FL 33136, USA.
Abbo
Lilian
L
Pano
Jose R
JR
Gaynor
Jeffrey J
JJ
Tryphonopoulos
Panagiotis
P
Weppler
Debbie
D
Moon
Jang I
JI
Tzakis
Andreas G
AG
Morris
Michele I
MI
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D000077595:Famciclovir; D005260:Female; D015774:Ganciclovir / Q000627:therapeutic use; D006085:Graft Survival / Q000187:drug effects; D006562:Herpes Zoster / Q000188:drug therapy / Q000209:etiology*; D014645:Herpesvirus 3, Human / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D015075:2-Aminopurine; D015774:Ganciclovir; D000077595:Famciclovir